Soya protein ameliorates the metabolic abnormalities of dysfunctional adipose tissue of dyslipidaemic rats fed a sucrose-rich diet.
The present study investigates whether the replacement of dietary casein by soya protein isolate could be able to improve and/or even revert the morphological and metabolic abnormalities underlying the adipose tissue dysfunction of dyslipidaemic rats chronically fed (8 months) a sucrose-rich (62·5 %) diet (SRD). For this purpose, Wistar rats were fed a SRD for 4 months. From months 4 to 8, half the animals continued with the SRD and the other half were fed a SRD in which the source of protein, casein, was substituted by soya. The control group received a diet in which the source of carbohydrate was maize starch. Compared with the SRD-fed group, the results showed that: (1) soya protein decreased body-weight gain, limited the accretion of visceral adiposity and decreased adipose tissue cell volume without changes in total cell number; (2) soya protein increased the protein mass expression of PPARγ, which was significantly reduced in the fat pad of the SRD-fed rats; (3) the activity of the enzymes involved in the de novo lipogenesis of adipose tissue was significantly decreased/normalised; (4) soya protein corrected the inhibitory effect of SRD upon the anti-lipolytic action of insulin, reduced basal lipolysis and normalised the protein mass expression of GLUT-4. Dyslipidaemia, glucose homeostasis and plasma leptin levels returned to control values. The present study provides data showing the beneficial effects of soya protein to improve and/or revert the adipose tissue dysfunction of a dyslipidaemic insulin-resistant rat model and suggests that soya could maintain the functionality of the adipose tissue-liver axis improving/reverting lipotoxicity.
Department of Biochemistry, School of Biochemistry, University of Litoral, Ciudad Universitaria, Paraje El Pozo, CC 242 (3000), Santa Fe, Argentina.
María E
ME
Oliva
Dante
D
Selenscig
María E
ME
D'Alessandro
Adriana
A
Chicco
Yolanda B
YB
Lombardo
D017667:Adipocytes / Q000378:metabolism / Q000473:pathology; D052436:Adipose Tissue, White / Q000378:metabolism* / Q000473:pathology; D050154:Adiposity; D000818:Animals; D001835:Body Weight; D048429:Cell Size; D019422:Dietary Sucrose / Q000009:adverse effects*; D050171:Dyslipidemias / Q000178:diet therapy* / Q000378:metabolism* / Q000473:pathology; D002149:Energy Intake; D004822:Epididymis; D015309:Glucose Clamp Technique; D051275:Glucose Transporter Type 4 / Q000378:metabolism; D007333:Insulin Resistance; D050155:Lipogenesis; D008066:Lipolysis; D008297:Male; D047495:PPAR gamma / Q000378:metabolism; D014674:Plant Proteins, Dietary / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D030262:Soybean Proteins / Q000627:therapeutic use*
D019422:Dietary Sucrose; D051275:Glucose Transporter Type 4; D047495:PPAR gamma; D014674:Plant Proteins, Dietary; C495694:Slc2a4 protein, rat; D030262:Soybean Proteins